Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-12-04

Clinical Trial Update: Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of nivolumab as neo-adjuvant immunotherapy in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • nivolumab (nivolumab)

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-12-04